Gofen & Glossberg’s Sorrento Therapeutics, Inc. SRNE Stock Holding History

Gofen & Glossberg’s Portfolio SRNE Stock Details SRNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-10,000	Closed	-$17K	–	491
2017 Q3	$17K	Hold	10,000	–	–	﹤0.01%	464
2017 Q2	$20K	Hold	10,000	–	–	﹤0.01%	460
2017 Q1	$40K	Hold	10,000	–	–	﹤0.01%	467
2016 Q4	$49K	Hold	10,000	–	–	﹤0.01%	446
2016 Q3	$77K	Hold	10,000	–	–	﹤0.01%	437
2016 Q2	$56K	Hold	10,000	–	–	﹤0.01%	438
2016 Q1	$54K	Hold	10,000	–	–	﹤0.01%	450
2015 Q4	$87K	Hold	10,000	–	–	﹤0.01%	434
2015 Q3	$84K	Buy	+10,000	New	+$159K	﹤0.01%	439

Other funds holding SRNE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

WCM

Wildcat Capital Management New York $229M AUM 132.65% 1-Year Est. Return

Intellectus Partners San Francisco, California $578M AUM 49.48% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $203M AUM 34.78% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Gofen & Glossberg's SRNE Position: Q4 2017 in Review

Gofen & Glossberg sold out of Sorrento Therapeutics, Inc. (SRNE) in Q4 2017, closing a stake of 10,000 shares — an estimated $17K sold.

Gofen & Glossberg first reported a position in SRNE in Q3 2015 and held it in 9 quarters. The position peaked at $87K in Q4 2015. 46 funds tracked by Wall St. Rank hold SRNE as of Q4 2017.

Gofen & Glossberg reported no remaining Sorrento Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
Gofen & Glossberg sold 10,000 Sorrento Therapeutics, Inc. shares in Q4 2017, an estimated $17K.
Gofen & Glossberg first reported a position in Sorrento Therapeutics, Inc. in Q3 2015 and held it in 9 quarters.
Gofen & Glossberg's Sorrento Therapeutics, Inc. position peaked at $87K in Q4 2015.
46 funds tracked by Wall St. Rank held Sorrento Therapeutics, Inc. as of Q4 2017.

Based on Gofen & Glossberg's 13F filing for Q4 2017, filed 11 Jan 2018.